Full metadata record

DC FieldValueLanguage
dc.contributor.author이상빈-
dc.contributor.author김지연-
dc.contributor.author심가용-
dc.contributor.author김선일-
dc.contributor.author한수은-
dc.contributor.author김광명-
dc.contributor.author권익찬-
dc.contributor.authorYongseok Choi-
dc.contributor.authorYoung Bong Kim-
dc.contributor.authorChan-Wha Kim-
dc.contributor.author오유경-
dc.date.accessioned2015-12-03T00:55:33Z-
dc.date.available2015-12-03T00:55:33Z-
dc.date.issued201212-
dc.identifier.citationVOL 164, NO 2, 213-220-
dc.identifier.issn01683659-
dc.identifier.other39080-
dc.identifier.urihttp://pubs.kist.re.kr/handle/201004/44381-
dc.description.abstractNanoparticles have demonstrated potential for promoting drug delivery to tumor sites and enhancing uptake. Here, we report tetraiodothyroacetic acid (tetrac) as a promising new targeting moiety for delivery of anticancer drugs to tumor tissues. Tetrac, an antagonist that blocks the binding of thyroid hormone to integrin αvβ3, was covalently linked to the activated end of pegylated lipid and used to formulate tetractagged pegylated liposomes (TPL). After incubating with TPL for 9 h, cellular accumulation efficiency into A375 human melanoma cells, which express integrin αvβ3 at high density, was high (98.5%±0.5% of cells), whereas that in KB cells, which express integrin at a very low density, was much lower (35.1%±4.5%). Molecular imaging revealed that TPL preferentially distributed to tumor tissues after systemic administration in mice, where as non-targeting pegylated liposomes were distributed to tumors at background levels. Treatment with the alkyl lysophospholipid anticancer drug edelfosine, encapsulated in TPL, significantly reduced the survival of A375 tumor cells compared to cells treated with edelfosine in pegylated liposomes or with lysophosphatidylcholine encapsulated in TPL. Moreover, intravenous administration of edelfosine in TPL significantly reduced the growth of tumors and prolonged the survival of A375-xenografted mice, providing 100% protection for up to 50 days and some protection until 66 days (0% survival endpoint). In contrast, no untreated mice or mice treated with edelfosine-loaded pegylated liposomes survived up to 50 or 48 days, respectively, after tumor inoculation. These results suggest the potential of tetrac as a new ligand moiety for enhancing the delivery of anticancer drug-loaded nanoparticles to tumors and enhancing the therapeutic efficacy of encapsulated anticancer drugs.-
dc.publisherJournal of controlled release-
dc.subjectTetraiodothyroacetic acid-
dc.subjectIntegrin receptor-
dc.subjectLiposome-
dc.subjectAnticancer drug-
dc.subjectEdelfosine-
dc.titleTetraiodothyroacetic acid-tagged liposomes for enhanced delivery of anticancer drug to tumor tissue via integrin receptor-
dc.typeArticle-
Appears in Collections:
KIST Publication > Article
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE